{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:30:53Z","timestamp":1761093053672,"version":"build-2065373602"},"reference-count":46,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T00:00:00Z","timestamp":1406073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:p>Hemophilia A (<jats:styled-content style=\"fixed-case\">HA<\/jats:styled-content>) represents one of the most common genetic bleeding disorders worldwide and results from a deficiency in factor <jats:styled-content style=\"fixed-case\">VIII<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">FVIII<\/jats:styled-content>). The mainstay of treatment for <jats:styled-content style=\"fixed-case\">HA<\/jats:styled-content> is repletion of <jats:styled-content style=\"fixed-case\">FVIII<\/jats:styled-content>. Numerous plasma\u2010derived and recombinant factor concentrates are available, each with clinical advantages and disadvantages. Nonfactor products including desmopressin and antifibrinolytic agents can also be used, depending on the clinical situation and severity of <jats:styled-content style=\"fixed-case\">FVIII<\/jats:styled-content> deficiency. Turoctocog alfa is the most recent addition to recombinant <jats:styled-content style=\"fixed-case\">FVIII<\/jats:styled-content> concentrates available for the treatment of <jats:styled-content style=\"fixed-case\">HA<\/jats:styled-content>. Pharmacokinetic trials in animals and humans have demonstrated characteristics similar to those of other recombinant <jats:styled-content style=\"fixed-case\">FVIII<\/jats:styled-content> concentrates. Clinical trials have supported efficacy and safety in the management of <jats:styled-content style=\"fixed-case\">HA<\/jats:styled-content> in treatment\u2010experienced patients; study results of turoctocog alfa in treatment\u2010na\u00efve patients are pending. A smaller study in hemophilic patients undergoing surgery has demonstrated positive results. Although turoctocog alfa was approved by the U.S. Food and Drug Administration in 2013, it will not be available on the market until 2015. Turoctocog alfa appears to be a safe and effective alternative to currently available recombinant <jats:styled-content style=\"fixed-case\">FVIII<\/jats:styled-content> concentrates; however, its place in therapy among these products has yet to be elucidated.<\/jats:p>","DOI":"10.1002\/phar.1469","type":"journal-article","created":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T07:51:26Z","timestamp":1406101886000},"page":"1091-1101","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Turoctocog Alfa for the Treatment of Hemophilia A"],"prefix":"10.1002","volume":"34","author":[{"given":"Niyati H.","family":"Vakil","sequence":"first","affiliation":[{"name":"Department of Pharmacy Cedars\u2010Sinai Medical Center Los Angeles California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Fujinami","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Cedars\u2010Sinai Medical Center Los Angeles California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Martin\u2010Stone","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Cedars\u2010Sinai Medical Center Los Angeles California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,23]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S6885"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2013.06.002"},{"key":"e_1_2_6_4_1","unstructured":"Share: Quarterly Update for Investors from Novo Nordisk [November 2013]. Available fromhttp:\/\/www.novonordisk.com\/images\/investors\/share_magazine\/2013\/88017_1-12_H15450_Share_Nov_2013_UK_LR.pdf. Accessed February 3 2014."},{"key":"e_1_2_6_5_1","unstructured":"How Hemophilia is inherited. Centers for Disease Control and Prevention Web site. Available fromhttp:\/\/www.cdc.gov\/ncbddd\/hemophilia\/inheritance-pattern.html. Accessed February 16 2014."},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02909.x"},{"key":"e_1_2_6_7_1","first-page":"519","volume-title":"Transfusion medicine and hemostasis: clinical and laboratory aspects","author":"Abshire TC","year":"2013"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders","volume":"90","author":"Mannucci PM","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02909.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03507.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aet154"},{"key":"e_1_2_6_12_1","first-page":"1","article-title":"Fibrinolytic inhibitors in the management of bleeding disorders","volume":"42","author":"Tengborn L","year":"2007","journal-title":"Treatment of Hemophilia"},{"volume-title":"Amicar (aminocaproic acid) package insert","year":"2007","author":"Hospira, Inc.","key":"e_1_2_6_13_1"},{"volume-title":"Cyklokapron (tranexamic acid) package insert","year":"2013","author":"Pfizer Pharmaceuticals, Inc","key":"e_1_2_6_14_1"},{"volume-title":"Desmopressin acetate injection package insert","year":"2007","author":"Hospira Inc","key":"e_1_2_6_15_1"},{"key":"e_1_2_6_16_1","first-page":"175","volume-title":"Transfusion medicine and hemostasis: clinical and laboratory aspects","author":"Shaz BH","year":"2013"},{"volume-title":"Manual of perioperative care in adult cardiac surgery","year":"2011","author":"Bojar RM","key":"e_1_2_6_17_1"},{"key":"e_1_2_6_18_1","first-page":"729","volume-title":"Transfusion medicine and hemostasis: clinical and laboratory aspects","author":"Dunn AL","year":"2013"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.429"},{"volume-title":"Humate\u2010P (antihemophilic factor\/von Willebrand Factor Complex (human)) package insert","year":"2013","author":"CSL Behring GmbH","key":"e_1_2_6_20_1"},{"volume-title":"Alphanate (antihemophilic factor\/von Willebrand Factor complex (human)) package insert","year":"2007","author":"Grifols Biologics Inc","key":"e_1_2_6_21_1"},{"volume-title":"Koate\u2010DVI (antihemophilic factor (human)) package insert","year":"2011","author":"Kedrion Biopharma, Inc","key":"e_1_2_6_22_1"},{"volume-title":"Hemofil\u2010M (antihemophilic factor (human))","year":"2012","author":"Baxter HealthCare Corp","key":"e_1_2_6_23_1"},{"volume-title":"Monoclate\u2010P (antihemophilic factor (human))","year":"2007","author":"Behring CSL","key":"e_1_2_6_24_1"},{"volume-title":"Recombinate (antihemophilic factor (recombinant))","year":"2010","author":"Baxter Healthcare Corp","key":"e_1_2_6_25_1"},{"volume-title":"Kogenate (antihemophilic factor (recombinant))","year":"2013","author":"Bayer HealthCare LLC","key":"e_1_2_6_26_1"},{"volume-title":"Helixate FS (antihemophilic factor (recombinant))","year":"2013","author":"Behring CSL","key":"e_1_2_6_27_1"},{"volume-title":"Advate (antihemophilic factor (recombinant))","year":"2010","author":"Baxter HealthCare Corp","key":"e_1_2_6_28_1"},{"volume-title":"NovoEight (antihemophilic factor (recombinant))","year":"2013","author":"Novo Nordisk, Inc","key":"e_1_2_6_29_1"},{"volume-title":"Xyntha (antihemophilic factor (recombinant))","year":"2012","author":"Wyeth Pharmaceuticals, Inc","key":"e_1_2_6_30_1"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00650.x"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A338"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830170111"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830450305"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02135.x"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02333.x"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02608.x"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02780.x"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02896.x"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02495.x"},{"key":"e_1_2_6_41_1","unstructured":"Novo Nordisk(2013)NovoEight (turoctocog alfa) receives approval from the FDA (16 Oct 2013) [Press release]. Available fromhttp:\/\/www.novonordisk.com\/press\/news\/news.asp?sShowsNewsItemsGUID=32394294-5c92-4964-a723-6b8fbc4d9059&sShowLanguageCode=end-GB. Accessed January 14 2014."},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12159"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12165"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12371"},{"issue":"3","key":"e_1_2_6_45_1","first-page":"101","article-title":"Surgery with turoctocog alfa: efficacy and safety in bleeding prevention during surgical procedures\u2010results from the guardian trials","volume":"98","author":"Santagostino E","year":"2013","journal-title":"Haematologica"},{"key":"e_1_2_6_46_1","unstructured":"Novo Nordisk.Safety and Efficacy of turoctocog alfa in prevention and treatment of bleeds in previously untreated children with hemophilia A (guardian 4). In: Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available fromhttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT1493778?term=turoctocog+alfa&rank=1. NLM Identifier: NCT01493778. Accessed January 14 2014."},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-382846"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1469","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1469","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:00:09Z","timestamp":1761040809000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,23]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1002\/phar.1469"],"URL":"https:\/\/doi.org\/10.1002\/phar.1469","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2014,7,23]]},"assertion":[{"value":"2014-07-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}